- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01922752
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
November 5, 2021 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
The primary objective is to determine the maximum tolerated dose (MTD), safety, and tolerability of oral CEP-37440 administered daily to patients with advanced or metastatic solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States
- Teva Investigational Site 10689
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Teva Investigational Site 10687
-
-
Texas
-
San Antonio, Texas, United States
- Teva Investigational Site 10686
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have histologic or cytologic evidence of a solid neoplasm for which no standard therapy is available, or have progressed despite standard therapy, or are intolerant to standard therapy.
- Patients must have evidence of recurrent, locally advanced, or metastatic disease.
- Patients can either have had no prior anticancer therapy, multiple lines of either prior chemotherapy/biologic therapy/experimental therapy or, if the patient has anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), prior crizotinib.
- Patients must have a predicted life expectancy of more than 3 months.
- Patients must have presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.
- Patients must have an ECOG performance score of 0, 1, or 2.
- Patients with central nervous system (CNS) metastases will be allowed on this study. Patients may have received surgical and/or radiation treatment. The metastases must be neurologically stable, on or off corticosteroids. Patients can have low level, asymptomatic brain lesions that do not require surgical/radiation intervention acutely. Patients with symptomatic lesions with impending neurologic compromise should be appropriately treated with high dose steroids/radiation and may be re-evaluated for this study when neurologically stable.
- Patients must have completed any prior anticancer treatment and must have recovered from any acute toxicities. The period between the last dose of prior treatment and the first dose of study drug treatment must be at least 1 week for radiotherapy and at least 2 to 3 weeks for all other modalities of therapy including chemotherapy, monoclonal antibody therapy, immunotherapy, other investigational drugs, or other kinase inhibitors.
- Other criteria apply.
Exclusion Criteria:
- The patient has ongoing or active infection requiring parenteral antibiotics.
- The patient has uncontrolled hypertension despite adequate therapy (ie, systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2 separate occasions separated by 1 week).
- The patient has uncontrolled diabetes mellitus (despite therapeutic intervention) and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
- The patient has an active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers for which they are treated with curative intent, and no known active disease in the 3 years prior to enrollment.
- The patient has a primary brain tumor. Patients may have brain metastases from another primary site.
- The patient has QTcF interval greater than 450 msec, has a known history of QTcF prolongation, is taking medications known to prolong QTcF, or has a history of torsade de pointes.
- The patient has a prior ALK-inhibitor-related toxicity or any other prior therapy-related acute toxicity that has not resolved prior to the first dose of study drug.
- Other criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CEP-37440
|
CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily. Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: 8 months
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Response (TTR)
Time Frame: 8 months
|
The time interval from the date of first dose to the first documented response (complete or partial response)
|
8 months
|
Number of participants with adverse events
Time Frame: From signing of the informed consent to the end of the follow-up visit (approximately Month 10)
|
From signing of the informed consent to the end of the follow-up visit (approximately Month 10)
|
|
Time to Progression (TTP)
Time Frame: 8 months
|
The time interval from date of first dose to first documented disease progression
|
8 months
|
Progression-free Survival (PFS)
Time Frame: 10 months
|
Time interval from date of first does to first documented disease progression or death from any cause (whichever occurs first)
|
10 months
|
Time to New Metastases (TTNM)
Time Frame: 8 months
|
Time interval from date of first dose to first documented new metastatic lesion not reported at baseline
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 12, 2013
First Submitted That Met QC Criteria
August 12, 2013
First Posted (Estimate)
August 14, 2013
Study Record Updates
Last Update Posted (Actual)
November 12, 2021
Last Update Submitted That Met QC Criteria
November 5, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C37440/1108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
Clinical Trials on CEP-37440
-
CephalonCompleted
-
CephalonCompletedPsoriasisUnited States
-
CephalonH. Lundbeck A/S; The Parkinson Study GroupTerminatedParkinson DiseaseUnited States, Canada, Puerto Rico
-
University of Michigan Rogel Cancer CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate CarcinomaUnited States
-
New Approaches to Neuroblastoma Therapy ConsortiumNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States, Canada
-
Edwards LifesciencesCompletedCoronary Artery Disease | Heart Failure | Aortic Valve Stenosis | Aortic Valve Insufficiency | Aortic Valve DisorderCanada, United States, Austria, Germany, Spain, United Kingdom
-
Cephalon, Inc.CompletedSystemic Lupus ErythematosusUnited States, Belgium, Czechia, France, Germany, Hungary, Poland, Portugal, Spain, Ukraine, United Kingdom
-
Cephalon, Inc.TerminatedSystemic Lupus ErythematosusUnited States, Belgium, Czechia, France, Germany, Hungary, Poland, Portugal, Spain, Ukraine, United Kingdom
-
Augusta UniversityCompletedHypersensitivity | Constipation | HyposensitivityUnited States